SCHEMBL71769

SCHEMBL71769

O=C(CCl)OP(=O)(OC(=O)CCl)OC(=O)CCl

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71770 0.80
SCHEMBL939429 0.71 ALDH1A1 (0.39) TSHRALDH1A1
SCHEMBL8568659 0.71 KDM4E (0.33) ALDH1A1
SCHEMBL18614747 0.69
SCHEMBL8598262 0.67 TSHR (0.44) TSHRALDH1A1
SCHEMBL16026 0.67
SCHEMBL5354391 0.67
SCHEMBL23827519 0.67 LDHA (0.40) TSHR
SCHEMBL17606428 0.65 MMP1 (0.43) ALDH1A1
SCHEMBL4598746 0.65 ALDH1A1 (0.52) TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4343 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1659178-B1 A process for the purification or production of a MAGE protein GLAXOSMITHKLINE BIOLOG SA (BE) 2010-03-31 EP claimed
EP-3620473-B1 NOVEL HETERODIMERIC PROTEINS XENCOR INC (US) 2026-05-27 EP disclosed
EP-4748862-A2 HETERODIMERIC PROTEINS Xencor, Inc. (US) 2026-05-27 EP disclosed
EP-3865514-B9 BISPECIFIC ANTIBODY BINDING DLL3 AND CD3 AMGEN RES MUNICH GMBH (DE) 2026-05-20 EP disclosed
US-12630650-B2 Engineered IgA antibodies and methods of use TIGATX, INC. (US) 2026-05-19 US disclosed
US-20260132199-A1 ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 AMGEN RES MUNICH GMBH (DE) 2026-05-14 US disclosed
EP-4741424-A2 FC VARIANTS WITH ALTERED BINDING TO FCRN Xencor, Inc. (US) 2026-05-13 EP disclosed
EP-3817770-B1 ANTI-STEAP1 ANTIGEN-BINDING PROTEIN AMGEN INC (US) 2026-05-06 EP disclosed
US-12617818-B2 Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them UNIVERSITY OF NORTH TEXAS (US) 2026-05-05 US disclosed
US-12617853-B2 Low pH pharmaceutical composition comprising T cell engaging antibody constructs Amgen Research (Munich), GmbH (DE) 2026-05-05 US disclosed
EP-0420936-A1 PURIFIED UBIQUITIN HYDROLASE, DNA SEQUENCES ENCODING SAME, AND ITS USE IN RECOVERING POLYPEPTIDES. GENENTECH INC (US) 1991-04-10 EP disclosed
WO-1991001133-A1 T CELL RECEPTOR PEPTIDES AS THERAPEUTICS FOR AUTOIMMUNE AND MALIGNANT DISEASE VANDENBARK ARTHUR ALLEN (US) 1991-02-07 WO disclosed
WO-1991000292-A1 COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF NATRIURETIC PROTEIN RECEPTOR B AND METHODS OF USE GENENTECH, INC. (US) 1991-01-10 WO disclosed
WO-1990013649-A1 PRODUCTION OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR AND DNA ENCODING SAME GENENTECH, INC. (US) 1990-11-15 WO disclosed
WO-1990013643-A2 GLYCOPROTEIN HORMONE RECEPTOR MOLECULES GENENTECH, INC. (US) 1990-11-15 WO disclosed
EP-0391088-A2 Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy CENTER FOR BLOOD RESEARCH LABORATORIES, INC. (US) 1990-10-10 EP disclosed
WO-1990010453-A1 USE OF INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1990-09-20 WO disclosed
EP-0387701-A1 Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma Boehringer Ingelheim Pharmaceuticals Inc. (US) 1990-09-19 EP disclosed
EP-0387668-A1 Intercellular adhesion molecule - 2 and its binding ligands CENTER FOR BLOOD RESEARCH LABORATORIES, INC. (US) 1990-09-19 EP disclosed
WO-1989012678-A1 PURIFIED UBIQUITIN HYDROLASE, DNA SEQUENCES ENCODING SAME, AND ITS USE IN RECOVERING POLYPEPTIDES GENENTECH, INC. (US) 1989-12-28 WO disclosed